TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Brief Summary: This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and immunogenicity of treatment with reslizumab in patients with eosinophilic asthma.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: huMAb OX40L; Type: EXPERIMENTAL; Interventions: Drug: huMAb OX40L | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: huMAb OX40L; Assigned to Arm(s): huMAb OX40L | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Benralizumab 30 mg q.4 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 30 mg q.8 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 30 mg q.4 weeks, Benralizumab 30 mg q.8 weeks | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo (for Dupilumab); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Dupilumab), Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone/Salmeterol combination therapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone monotherapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Levalbuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Collaborative Care for Depressed Elders in China
Brief Summary: Using a randomized controlled design, the investigators will examine whether the DCM is an effective treatment for patients with late life depression in urban China. Our specific aims are: (1) to determine whether the DCM intervention results in improved outcomes compared with CAU at both the provider (e.g., greater adherence to quality indicators) and patient levels (e.g., greater reduction in depressive symptoms); and (2) to compare DCM with CAU with regard to a range of outcomes in other pertinent domains, both at the provider (e.g., improvements in knowledge/attitudes) and patient (e.g., functioning, satisfaction) levels. The study will take place in 16 primary care clinics (PCCs) randomly assigned to deliver either DCM or CAU (8 clinics each) to 320 patients (aged≥60 years) with major depression (20/clinic; n=160 in each treatment condition). In the DCM arm, PCPs will prescribe 16 weeks of antidepressant medication according to the TG protocol. CMs monitor the progress of treatment and side effects, educate patients/family, and facilitate communication between providers; psychiatrists will provide weekly group psychiatric consultation and CM supervision. Patients in both DCM and CAU arms will be assessed by clinical research coordinators at baseline, 4, 8, 12, 18, and 24 months. HDRS, MMSE, CAS, SF-12, Treatment Stigma and the Client Satisfaction Questionnaire will be used to assess patients' outcomes; and clinic practices, attitudes/knowledge, and satisfaction will be providers' outcomes.


Options:
A: Arm Label: Depression Care Management; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Arm Label: Care as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Depression Care Management
B: Intervention Type: BEHAVIORAL; Name: Care manager outreach and monitoring; Assigned to Arm(s): N/A
C: Arm Label: Arm 1: Collaborative Care Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Care Interventions | Arm Label: Arm 2: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Collaborative Care Interventions; Assigned to Arm(s): Arm 1: Collaborative Care Intervention
D: Arm Label: Depressed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation; Treatment recommendations, Drug: Pharmacotherapy | Arm Label: Depressed Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Non-Depressed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Treatment recommendations; Assigned to Arm(s): Depressed Intervention | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): Depressed Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Depressed Usual Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gemcitabine Plus Paclitaxel (GT) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer
Brief Summary: This is a prospective, multi-center, open-labeled, randomized phase III clinical trial comparing overall response rate (ORR), progression free survival (PFS), overall survival (OS) and toxicity obtained with gemcitabine cisplatin combination (GP) versus gemcitabine paclitaxel combination (GT).


Options:
A: Arm Label: cisplatin and cetuximab; Type: EXPERIMENTAL; Interventions: Drug: cetuximab, cisplatin | Arm Label: cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin | Intervention Type: DRUG; Name: cetuximab, cisplatin; Assigned to Arm(s): cisplatin and cetuximab | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): cisplatin
B: Arm Label: Gemcitabine,cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine,cisplatin | Arm Label: Gemcitabine, Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine, Paclitaxel | Intervention Type: DRUG; Name: Gemcitabine,cisplatin; Assigned to Arm(s): Gemcitabine,cisplatin | Intervention Type: DRUG; Name: Gemcitabine, Paclitaxel; Assigned to Arm(s): Gemcitabine, Paclitaxel
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor), Drug: Carboplatin | Arm Label: 2.; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor), Drug: Paclitaxel | Arm Label: 3.; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor), Drug: Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): 2. | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2. | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): 3. | Intervention Type: DRUG; Name: Paclitaxel + Carboplatin; Assigned to Arm(s): 3.
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: AZ2281 + Carboplatin | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: AZ2281 + Carboplatin | Intervention Type: DRUG; Name: AZ2281 + Carboplatin; Assigned to Arm(s): Arm 1, Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients With Stable Ischemic Stroke
Brief Summary: The primary purpose of the clinical study is to determine the safety of a modified stem cell SB623 when administered to chronic, stable ischemic stroke patients. A second purpose is to determine whether SB623 might improve stroke symptoms. Chronic, stable ischemic stroke patients must be between 6 and 60 months after their stroke, and with only this one prior stroke, and with no further improvement from physical therapy.


Options:
A: Arm Label: Bone marrow transplantation low dose; Type: EXPERIMENTAL; Interventions: Drug: Autologous bone marrow mononuclear cell intra-arterial injection | Arm Label: Bone marrow transplantation high dose; Type: EXPERIMENTAL; Interventions: Drug: Autologous bone marrow mononuclear cell intra-arterial injection | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Autologous bone marrow mononuclear cell intra-arterial injection; Assigned to Arm(s): Bone marrow transplantation high dose, Bone marrow transplantation low dose
B: Arm Label: SB623 Implant (2.5M); Type: EXPERIMENTAL; Interventions: Biological: SB623 | Arm Label: SB623 Implant (5.0M); Type: EXPERIMENTAL; Interventions: Biological: SB623 | Arm Label: SB623 Implant (10.0M); Type: EXPERIMENTAL; Interventions: Biological: SB623 | Intervention Type: BIOLOGICAL; Name: SB623; Assigned to Arm(s): SB623 Implant (10.0M), SB623 Implant (2.5M), SB623 Implant (5.0M)
C: Arm Label: HLCM051 (MultiStem); Type: EXPERIMENTAL; Interventions: Biological: HLCM051 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: HLCM051; Assigned to Arm(s): HLCM051 (MultiStem) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: bone marrow stem cells; Type: OTHER; Interventions: Procedure: Infusion on autologous CD34+ stem cells into middle cerebral artery | Intervention Type: PROCEDURE; Name: Infusion on autologous CD34+ stem cells into middle cerebral artery; Assigned to Arm(s): bone marrow stem cells

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Decision Support for Women With a History of Gestational Diabetes
Brief Summary: The investigators hypothesize that computer-assisted decision support will increase the percentage of women with a history of gestational diabetes who receive appropriate follow-up screening.

Specific Aim 1: Develop an algorithm to identify cases of gestational diabetes among patients in the Partners Health Care system using administrative and laboratory data.

Specific Aim 2: Assess primary care provider knowledge, attitudes, beliefs, and barriers to compliance regarding screening guidelines for women with a history of gestational diabetes.

Specific Aim 3: Test whether a computer-assisted decision support tool to identify patients with a GDM history and prompt screening will increase compliance with guidelines. The investigators hypothesize that decision support will significantly increase in the percentage of women screened.


Options:
A: Arm Label: Electronic Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support for ARI Management | Arm Label: Paper Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support for ARI Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision Support for ARI Management; Assigned to Arm(s): Electronic Decision Support, Paper Decision Support
B: Arm Label: EMR reminder; Type: EXPERIMENTAL; Interventions: Other: EMR Reminder | Arm Label: EMR reminder + Panel management; Type: EXPERIMENTAL; Interventions: Other: EMR Reminder + Panel management | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: EMR Reminder; Assigned to Arm(s): EMR reminder | Intervention Type: OTHER; Name: EMR Reminder + Panel management; Assigned to Arm(s): EMR reminder + Panel management
C: Intervention Type: DEVICE; Name: Real time computer prompted trauma algorithms; Assigned to Arm(s): N/A
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Quality improvement initiative | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Quality improvement initiative; Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is a Knee Arthroscopy of Any Benefit for the Middleaged Patient With Meniscal Symptoms?
Brief Summary: The purpose of this study is to determine whether a knee arthroscopy is effective in the treatment of middleaged patients with meniscal symptoms also receiving a standardised exercise program.


Options:
A: Arm Label: Arthroscopy plus Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Arthroscopy plus Medical Management, Other: Medical Management | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Arthroscopy plus Medical Management; Assigned to Arm(s): Arthroscopy plus Medical Management | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Arthroscopy plus Medical Management
B: Arm Label: Meniscus Injury Patients; Type: N/A; Interventions: Procedure: Arthroscopic Meniscus Surgery | Intervention Type: PROCEDURE; Name: Arthroscopic Meniscus Surgery; Assigned to Arm(s): Meniscus Injury Patients
C: Arm Label: Arthroscopy; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic meniscal repair or resection | Arm Label: Exercise and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise and education | Intervention Type: PROCEDURE; Name: Arthroscopic meniscal repair or resection; Assigned to Arm(s): Arthroscopy | Intervention Type: BEHAVIORAL; Name: Exercise and education; Assigned to Arm(s): Exercise and Education
D: Arm Label: Arthroscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Knee arthroscopy | Arm Label: Exercise therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Knee arthroscopy; Assigned to Arm(s): Arthroscopy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is a Knee Arthroscopy of Any Benefit for the Middleaged Patient With Meniscal Symptoms?
Brief Summary: The purpose of this study is to determine whether a knee arthroscopy is effective in the treatment of middleaged patients with meniscal symptoms also receiving a standardised exercise program.


Options:
A: Arm Label: Arthroscopic microfracture (MF); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Arthroscopic microfracture (MF) | Arm Label: Arthroscopic debridement (AD); Type: SHAM_COMPARATOR; Interventions: Procedure: Arthroscopic debridement (AD) | Intervention Type: PROCEDURE; Name: Arthroscopic microfracture (MF); Assigned to Arm(s): Arthroscopic microfracture (MF) | Intervention Type: PROCEDURE; Name: Arthroscopic debridement (AD); Assigned to Arm(s): Arthroscopic debridement (AD)
B: Arm Label: Arthroscopy plus Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Arthroscopy plus Medical Management, Other: Medical Management | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Arthroscopy plus Medical Management; Assigned to Arm(s): Arthroscopy plus Medical Management | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Arthroscopy plus Medical Management
C: Arm Label: Arthroscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Knee arthroscopy | Arm Label: Exercise therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Knee arthroscopy; Assigned to Arm(s): Arthroscopy
D: Arm Label: Surgical; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic partial menisectomy, Other: Postoperative rehabilitative physical therapy | Arm Label: Nonoperative; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard physical therapy | Intervention Type: PROCEDURE; Name: Arthroscopic partial menisectomy; Assigned to Arm(s): Surgical | Intervention Type: OTHER; Name: Standard physical therapy; Assigned to Arm(s): Nonoperative | Intervention Type: OTHER; Name: Postoperative rehabilitative physical therapy; Assigned to Arm(s): Surgical

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intracranial Pressure in Experimental Models of Headache
Brief Summary: The purpose of this study is to determine whether increased pressure in the head is elevated in people who suffer from High Altitude Headache. We hypothesise that head pressure will be elevated in people with High Altitude Headache.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Aminophylline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline | Arm Label: Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methazolamide | Arm Label: Aminophylline+Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline+Methazolamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aminophylline; Assigned to Arm(s): Aminophylline | Intervention Type: DRUG; Name: Methazolamide; Assigned to Arm(s): Methazolamide | Intervention Type: DRUG; Name: Aminophylline+Methazolamide; Assigned to Arm(s): Aminophylline+Methazolamide
B: Arm Label: Telmisartan/nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Nifedipine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: ascent protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ascent protocol | Intervention Type: BEHAVIORAL; Name: ascent protocol; Assigned to Arm(s): 1, 2
D: Arm Label: Acetazolamide; Type: EXPERIMENTAL; Interventions: Drug: Acetazolamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose monohydrate | Intervention Type: DRUG; Name: Acetazolamide; Assigned to Arm(s): Acetazolamide | Intervention Type: DRUG; Name: Lactose monohydrate; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intracranial Pressure in Experimental Models of Headache
Brief Summary: The purpose of this study is to determine whether increased pressure in the head is elevated in people who suffer from High Altitude Headache. We hypothesise that head pressure will be elevated in people with High Altitude Headache.


Options:
A: Arm Label: Acetazolamide; Type: EXPERIMENTAL; Interventions: Drug: Acetazolamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose monohydrate | Intervention Type: DRUG; Name: Acetazolamide; Assigned to Arm(s): Acetazolamide | Intervention Type: DRUG; Name: Lactose monohydrate; Assigned to Arm(s): Placebo
B: Arm Label: Rhodiola crenulata-placebo sequence; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rhodiola crenulata, Drug: placebo | Arm Label: Placebo-Rhodiola crenulata sequence; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rhodiola crenulata, Drug: placebo | Intervention Type: DRUG; Name: Rhodiola crenulata; Assigned to Arm(s): Placebo-Rhodiola crenulata sequence, Rhodiola crenulata-placebo sequence | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo-Rhodiola crenulata sequence, Rhodiola crenulata-placebo sequence
C: Arm Label: Telmisartan/nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Nifedipine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Erythropoietin; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Erythropoietin; Assigned to Arm(s): Erythropoietin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intracranial Pressure in Experimental Models of Headache
Brief Summary: The purpose of this study is to determine whether increased pressure in the head is elevated in people who suffer from High Altitude Headache. We hypothesise that head pressure will be elevated in people with High Altitude Headache.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: ascent protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ascent protocol | Intervention Type: BEHAVIORAL; Name: ascent protocol; Assigned to Arm(s): 1, 2
B: Intervention Type: DRUG; Name: dexamethasone 8 mg bid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tadalafil 10mg bid; Assigned to Arm(s): N/A
C: Arm Label: Acetazolamide; Type: EXPERIMENTAL; Interventions: Drug: Acetazolamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose monohydrate | Intervention Type: DRUG; Name: Acetazolamide; Assigned to Arm(s): Acetazolamide | Intervention Type: DRUG; Name: Lactose monohydrate; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Aminophylline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline | Arm Label: Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methazolamide | Arm Label: Aminophylline+Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline+Methazolamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aminophylline; Assigned to Arm(s): Aminophylline | Intervention Type: DRUG; Name: Methazolamide; Assigned to Arm(s): Methazolamide | Intervention Type: DRUG; Name: Aminophylline+Methazolamide; Assigned to Arm(s): Aminophylline+Methazolamide

Answer: C